ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...
In December 2021, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko; Amgen, Inc and AstraZeneca AB), a thymic stromal lymphopoietin (TSLP) blocker, for the add-on ...
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
GULFPORT, LA, UNITED STATES, March 11, 2026 /EINPresswire.com/ — Medication management for Attention Deficit Disorder (ADD) often involves two primary categories of ...
Many patients with chronic obstructive pulmonary disease (COPD) have uncontrolled disease despite appropriate use of triple therapy. These patients often exhibit type 2 inflammation, as indicated by ...
Marc Dunoyer, Chief Executive Officer, Alexion, said: “The approval of first-in-class, Factor D inhibitor VOYDEYA marks an important advancement in the treatment of PNH and builds on our leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results